Unravelling the landscape of image-guided radiotherapy: a comprehensive overview

Sarma, Gautam; Kashya, Hrishikesh; Medhi, Partha Pratim; Kalita, Rupam; Lahkar, Dhanjit

doi:10.5603/pmp.100218

Palliat Med Pract

2024

DOI: 10.5603/pmp.100218

|View full text |Cite

Unravelling the landscape of image-guided radiotherapy: a comprehensive overview

Gautam Sarma,

Hrishikesh Kashya,

Partha Pratim Medhi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY)

Moreau,

China,

et al. 2024

JFB

View full text Add to dashboard Cite

Smart radiotherapy biomaterials (SRBs) include seed and liquid biomaterials designed to be employed as fiducial markers during radiotherapy while also delivering therapeutic drug payloads to enhance treatment outcomes. In this study, we investigate a novel Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY) biomaterial, which can be loaded with immunoadjuvants (anti-CD40 monoclonal antibody or Caflanone (FBL-03G)) at the point of care. The CLARITY biomaterial was investigated in an animal model of pancreatic cancer using C57BL6 mice. Mice were imaged before and at different points of time post-treatment to evaluate the potential of CLARITY biomaterial to provide imaging contrast similar to fiducials. This study also used cadavers to assess CLARITY’s potential to provide imaging contrast in humans. Results showed imaging contrast from computed tomography (CT) and magnetic resonance imaging (MRI) modalities for up to 30 days post-treatment, demonstrating potential for use as fiducials. A significant increase in survival (***, p = 0.0006) was observed for mice treated with CLARITY biomaterial loaded with immunoadjuvant for up to 10 weeks post-treatment compared to those without treatment. These initial results demonstrate the potential of CLARITY biomaterial to serve as a smart multifunctional radiotherapy biomaterial and provide the impetus for further development and optimization as a point-of-care technology for combination radiotherapy and immunotherapy.

show abstract

Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY)

Moreau,

China,

et al. 2024

JFB

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Unravelling the landscape of image-guided radiotherapy: a comprehensive overview

Cited by 1 publication

References 32 publications

Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY)

Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY)

Contact Info

Product

Resources

About